Repositorio Dspace

Immunisation schedule of the Pediatric Spanish Association: 2021 recommendations

Mostrar el registro sencillo del ítem

dc.contributor.author Álvarez-García, Francisco-José
dc.contributor.author Cilleruelo-Ortega, María-José
dc.contributor.author Álvarez-Aldean, Javier
dc.contributor.author Garcés-Sánchez, María
dc.contributor.author García-Sánchez, Nuria
dc.contributor.author Garrote-Llanos, Elisa
dc.contributor.author Hernández-Merino, Ángel
dc.contributor.author Iofrío-de-Arce, Antonio
dc.contributor.author Montesdeoca-Melián, Abian
dc.contributor.author Navarro-Gómez, María-Luisa
dc.contributor.author Ruiz-Contreras, Jesús
dc.date.accessioned 2025-11-19T12:39:03Z
dc.date.available 2025-11-19T12:39:03Z
dc.date.issued 2021-01
dc.identifier.issn 1695-4033
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/21110
dc.description.abstract The CAV-AEP annually publishes the immunisation schedule considered optimal for all children and adolescent resident in Spain, taking into account the available evidence. The 2+1 schedule is recommended (2, 4, and 11 months) with hexavalent vaccines (DTPa-VPI-Hib-HB) and with 13-valent pneumococcal conjugate.A 6-year booster is recommended, preferably with DTPa (if available), with a dose of polio for those who received 2+1 schemes, as well as vaccination with Tdpa in adolescents and in each pregnancy, preferably between 27 and 32 weeks. Rotavirus vaccine should be systematic for all infants. Meningococcal B vaccine, with a 2+1 schedule, should be included in routine calendar. In addition to the inclusion of the conjugated tetravalent meningococcal vaccine (MenACWY) at 12 years of age with catch up to 18 years, inclusive, the CAV recommends this vaccine to be also included at 12 months of age, replacing MenC. Likewise, it is recommended in those over 6 weeks of age with risk factors or who travel to countries with a high incidence of these serogroups. Two-dose schedules for triple viral (12 months and 3-4 years) and varicella (15 months and 3-4 years) will be used. The second dose could be applied as a tetraviral vaccine. Universal systematic vaccination against HPV is recommended, regardless of gender, preferably at 12 years, and greater effort should be made to improve coverage. The 9 genotype extends coverage for both genders.
dc.language.iso spa
dc.publisher EDICIONES DOYMA S A
dc.rights Atribución-NoComercial-SinDerivadas 3.0 España
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/3.0/es/ *
dc.subject.mesh Adolescent
dc.subject.mesh Child
dc.subject.mesh Female
dc.subject.mesh Humans
dc.subject.mesh Immunization Schedule
dc.subject.mesh Infant
dc.subject.mesh Male
dc.subject.mesh Spain
dc.subject.mesh Vaccination
dc.subject.mesh Vaccines, Combined
dc.title Immunisation schedule of the Pediatric Spanish Association: 2021 recommendations
dc.type info:eu-repo/semantics/article
dc.identifier.pmid 33419517
dc.relation.publisherversion https://linkinghub.elsevier.com/retrieve/pii/S1695403320304409
dc.identifier.doi 10.1016/j.anpedi.2020.10.002
dc.journal.title Anales de Pediatría
dc.identifier.essn 1695-9531


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial-SinDerivadas 3.0 España Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución-NoComercial-SinDerivadas 3.0 España

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta